Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.7% in the morning session after the company ...

THE European Medicines Agency on Friday recommended authorizing a twice-yearly injectable drug “lenacapavir” to prevent HIV and help end the virus’ transmission.

Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...

Overview: Quality Chemicals supplies HIV medicines to 14 countries in the region, with 17 million treatments sold last year, ...

Thousands of Kenyans are set to benefit from the roll-out of Lenacapavir injectable HIV preventive drug. The drug is the ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

What do health taxes, a twice-a-year anti-HIV jab, AI and a MAC have in common? They can all help plug the gap that the Trump administration’s HIV funding cuts have left ...

Discover key insights from Gilead Sciences' Q2 2025 earnings call, featuring Yeztugo's groundbreaking launch, upward guidance revisions, and strong ...